title: Efficacy of hypomethylating agents in therapy-related myelodysplastic syndromes.
abstract: We retrospectively assessed morphologic and cytogenetic responses to 5-azacytidine and decitabine in a cohort of 42 adult therapy-related myelodysplastic syndromes (tMDS) patients treated at Memorial Sloan-Kettering Cancer Center and in 2 industry-sponsored decitabine trials (D0007 and DACO-020). The overall response rate (complete remission+marrow CR+hematologic improvement) was 38%, including 6 patients with complete remission (14%), 6 with marrow CR with or without hematologic improvement (14%), and 4 with hematologic improvement alone (10%). We conclude that DNA methyltransferase inhibitors showed activity in tMDS that is roughly comparable to that seen in de novo MDS.
authors.affiliation: Department of Medicine, Leukemia Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA. Klimekv@mskcc.org
authors.forename: Virginia M
authors.initials: VM
authors.lastname: Klimek
authors.forename: Emily K
authors.initials: EK
authors.lastname: Dolezal
authors.forename: Michael T
authors.initials: MT
authors.lastname: Tees
authors.forename: Sean M
authors.initials: SM
authors.lastname: Devlin
authors.forename: Karen
authors.initials: K
authors.lastname: Stein
authors.forename: Alejandro
authors.initials: A
authors.lastname: Romero
authors.forename: Stephen D
authors.initials: SD
authors.lastname: Nimer
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D001374:Azacitidine / Q000627:therapeutic use; D000076123:DNA (Cytosine-5-)-Methyltransferase 1; D004248:DNA (Cytosine-5-)-Methyltransferases / Q000037:antagonists & inhibitors; D019175:DNA Methylation / Q000187:drug effects*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000139:chemically induced / Q000188:drug therapy*; D016609:Neoplasms, Second Primary / Q000139:chemically induced / Q000188:drug therapy*; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D000964:Antimetabolites, Antineoplastic; D000076123:DNA (Cytosine-5-)-Methyltransferase 1; D004248:DNA (Cytosine-5-)-Methyltransferases; D001374:Azacitidine